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Introduction
Together with peri-hilar cholangiocarcinoma and 
cholangiocarcinoma of  dista l  common bi le  duct , 
intrahepatic cholangiocarcinoma (ICC) is a subtype of 
the cholangiocarcinoma family, contributing to 20–25% 
all cholangiocarcinoma cases (1). Despite this rarity, it is 
the second most common primary liver cancer following 
hepatocellular carcinoma (HCC), accounting to 10% of 
all primary liver cancer (2). Unlike the more common 
extrahepatic cholangiocarcinoma, a rising incidence 
of ICC was observed worldwide. In United States, 
the incidence had increased from 0.32 per 100,000 in 
1975 to 0.85 per 100,000 in 1995 (3,4). Similar rise had 
been reported in both Far East and the West, such as 
Japan and United Kingdom (5,6). While some studies 
attributed it to different classification systems used by the 
epidemiological analysis (7), this rising trend has been 
stabilized in the last decade (8). Disease conditions like 
recurrent pyogenic cholangitis (RPC), choledochal cyst, 
biliary cirrhosis, primary sclerosing cholangitis (PSC), 
biliary papillomatosis/adenoma, alcoholic liver disease 
and parasitic infestations are known predisposing factors 
for development of ICC (9). Although diabetes mellitus, 
hepatitis B/C infection, nonalcoholic steatohepatitis, 
chronic pancreatitis, obesity and smoking are suggested 
to be associated with ICC (10), many ICCs are developed 
de novo  without any of the above factors (11,12). 
Histologically, ICC can be classified into three distinct 
subtypes: mass-forming, peri-ductal infiltrating and intra-
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ductal growth (13). Mass-forming ICCs are the most 
common subtypes and have the propensity of intrahepatic 
metastasis; peri-ductal infiltrating confers the worst 
prognosis with its tendency to disseminate via hilar 
lymphatics.
Investigation and diagnosis
Since most of the ICC developed at the periphery of the 
biliary tree, obstructive jaundice is uncommon and most 
patients present late due to its insidious onset (14), around 
12–30% of the ICC were diagnosed in asymptomatic 
patients (12,15) and curative surgery is possible only 
in about 40% of the patients (16). Cancer antigen 
19–9 elevation might be found in some of the patient but 
it is not diagnostic (17). Tumour biopsy with the use of 
immunohistochemical tests such as a positive cytokeratin 
(CK) 7, negative CK20, negative transcription termination 
factor RNA polymerase (TTF1), negative deletion in 
pancreatic cancer, locus 4 (DPC4) and negative caudal type 
homeobox2 (CDX2) are evidence support the diagnosis of 
primary ICC (18). Tumour biopsy is usually reserved for 
inoperable disease as the sampling process might risk needle 
tract and peritoneal seedling.
Cross-sectional imaging remains the most important 
investigation modality for ICC. The proportion of tumour 
cells and fibrous tissue possessed by the tumour would affect 
its enhancement pattern and appearance on CT scan (19).
The typical CT features of a mass-forming cholangiocarcinoma 
include homogeneous attenuation, irregular peripheral 
enhancement with gradual centripetal enhancement, 
capsular retraction, the presence of satellite nodules, and 
associated intra-hepatic ductal dilatation around the tumour 
(13,20-23). If ICC developed in background RPC, there 
may be co-existing hepaticolithiasis, dilated intrahepatic 
duct, atopic hepatic parenchyma and thrombosed portal vein 
to the diseased lobe (24). For peri-ductal infiltrative ICC, it 
appears as enhancing peri-ductal thickening around a dilated 
or narrowed intrahepatic bile duct without mass formation 
resembling that of infiltrative hilar cholangiocarcinoma (23). 
In case of intra-ductal type, it can have five imaging 
patterns, namely diffused and marked ductal ectasia with or 
without visible mass, intra-ductal polypoid mass within a 
dilated intra-hepatic duct, intra-ductal cast within a dilated 
duct and focal stricture associated with proximal ductal 
dilatation (25). However, due to presence of surrounding 
fibrous tissue, there is limitation for CT to delineate the 
extent of carcinoma and resectability can be determined 
in only 60% of the cases (26); another shortcoming of CT 
scan is it may not be able to differentiate PSC and ICC (27). 
ICCs are typically hypointense on T1 weighted and 
hyperintense on T2 weighted imaging in MRI. Peripheral 
enhancement and progressive concentric filling would be 
seen in delay phases of contrast MRI (28). However, some 
of the ICC exhibit atypical imaging features and by the 
same token, there are a number of mimickers for ICC. In 
cirrhotic patients, HCC with cirrhotic stroma, sclerosing 
HCC and cholangiohepatocellular carcinoma could have 
nearly identical imaging characteristics as ICC (29-31). 
Recent studies suggest that, use of a new liver specific 
MRI contrast, Gadolinium ethoxybenzyl dimeglumine, 
also known as gadoxetate disodium, can increase the 
conspicuity and better delineate characteristics of various 
liver tumours (32,33).
Fluorodeoxyglucose (FDG)-PET has a specific role in 
the management of ICC, some studies reported a high 
sensitivity and specificity of 85% for diagnosis of ICC 
(34,35), and small cholangiocarcinoma of 1 cm can also 
be detected, despite this is less sensitive in presence of 
inflammatory process or infiltrative type ICC (34,36,37). In 
addition, FDG-PET is more specific in picking up regional 
lymphadenopathy than CT scan, though it is not more 
sensitive (35,38).. While at most of the time, FDG-PET 
reveals a “hot” spot in the liver and do not differentiate 
ICC from other tumours, some investigators reported that 
FDG-PET can change the management of up to 30% of 
the patients with ICCs by detecting metastatic diseases 
(35,39,40). Therefore, FDG-PET should be considered 
in patients with systemic symptoms or locally advanced 
tumour.
Staging for intrahepatic cholangiocarcinoma (ICC)
Staging system plays an important role in prognosticating 
and guiding treatment of ICC. In 1997, The Liver 
Cancer Study Group of Japan (LCSGJ) first advocated 
an independent staging for ICC from HCC (41). There 
were two Japanese systems proposed by Yamasaki (13) and 
Okabayashi (42) respectively. The former one staged ICC 
by solitary tumour size cut-off at 2 cm, venous invasion and 
presence peritoneal metastasis while the other one employed 
presence of symptoms, lymph node metastasis, multifocal 
tumour, vascular invasion and peritoneal metastasis for 
staging. Outside Japan, AJCC/UICC classification is 
commonly used. Like the classification in Japan, size of 
tumour remains an important factor to assign the T-staging 
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in sixth edition AJCC/UICC (43). However, since this 
system was derived from data largely based on HCC patients, 
and due to the differences in carcinogenesis mechanism and 
tumor biology between HCC and ICC (44-48), AJCC/UICC 
sixth edition was criticized to be lacking of discriminatory 
ability. Subsequently, a large SEER cohort performed in 
2009 (49) demonstrated that tumour size is not associated 
with long-term survivals. The simplified staging system 
proposed was noted to have better discriminatory ability 
than AJCC/UICC sixth edition and superior discriminatory 
power when compared to Japanese staging systems (49). 
Based on these findings, the T-staging criteria in the latest 
AJCC/UICC seventh edition (50) exclude tumour size. 
In addition, a number of studies (45,49-57) validated the 
prognostic significance of vascular invasion and multiple 
tumour; with the latter being regarded as a worse parameter 
by some authors (52,53). Apart from the newly added criteria 
of peri-ductal infiltration as T4 disease, tumour involvement 
of regional lymph node is currently regarded as stage IVa 
disease instead of stage III disease as in the sixth edition. This 
is because the impact of lymph node metastasis on survival 
is even stronger than that of the vascular invasion and 
multifocal disease (58). Some studies suggest the number of 
lymph node metastasis (49,54,59,60) and the ratio of positive 
lymph node to examined lymph node (54) have implication 
on prognosis. However, there is no sub-classification of the 
extent of lymph node metastasis in the AJCC seventh edition, 
albeit, this staging system is externally and independently 
validated by the French Surgical Association (AFC)-IHCC 
2009 study group and hence recommended for both clinical 
and research purposes (61).
Surgical treatments of intrahepatic 
cholangiocarcinoma (ICC)
Resection remains the only hope of cure in patients with 
ICC (62-64), but for a multitude of reasons, R0 resection 
(macroscopic and microscopic negative margin) is only 
achieved in 32% to 96% of the cases (15,52,55,58,60-62, 
65-69). Intrahepatic metastasis and peritoneal deposits 
are some of the reasons for unresectability, some studies 
suggested that diagnostic laparoscopy can save unnecessary 
laparotomy from 27–36% of the cases (66,70). However, other 
studies reported that the sensitivity of staging laparoscopy 
in only 55% (66) and a high false negative rate (70). 
Furthermore, many of the unresectable cases are due to major 
vascular invasion or contralateral biliary system involvement 
that could only be confirmed with surgical dissection. 
Therefore, staging laparoscopy could not be recommended 
as a routine until further convincing data emerged.
Resection of ICC needs to be aggressive in order 
to obtain the best oncological outcomes (65,71,72). It 
has been suggested that, for mass forming type of ICC, 
operation should follow the principle of anatomical major 
hepatectomy, while for infiltrative types ICC, extrahepatic 
bile duct excision and lymph node dissection should be 
performed (73,74). Extended hepatectomy, bile duct 
reconstruction and vascular resection are frequently 
required, reported as up to 78%, 29% and 14% respectively 
(15,55,60,66,67,69,75,76), despite the complexity of the 
surgery, the reported morbidity and mortality in some 
centers can be as low as 6% and 1% (10,49,55) respectively. 
Therefore, hepatectomy for ICC is best to be performed in 
high volume center (77).
Advances of surgical technique and perioperative 
care allow many challenging ICC to become resectable, 
however, the prognosis for this group of patients remains 
poor with 5-year overall survival (OS) less than 40% in 
most recent series (Table 1). Regional lymphadenectomy and 
wider resection have been the area of active research in the 
hope that the survival could be further prolonged. Routine 
lymphadenectomy could theoretically enhance oncological 
clearance (74,80) and optimize pathological staging, 
however, the counter-argument is lymph node dissection 
does not seem to influence ultimate survival of ICC patients 
(57,81,82). While strong evidence is lacking, lymph node 
dissection is sensible when there is gross regional lymph 
node involvement. Concerning the resection margin issue, 
Table 1 OS of ICC patients following resection from recent series
Year Authors Number
Median 
survival, mo
5-yr OS 
(%)
2012 Fisher et al. (78) 58 23 –
2011 de Jong et al. (58) 449 27 31
2009 Shimada et al. (57) 104 – 34
2009 Choi et al. (79) 64 – 39
2008 Endo et al. (55) 77 36 –
2008 Nakagohri et al. (53) 56 – 32
2008 Tamandl et al. (54) 74 – 28
2008 Uenishi et al. (56) 133 – 29
2008 Paik et al. (52) 97 53 31
2005 Lang et al. (65) 83 26 21
OS, overall survival; ICC, intrahepatic cholangiocarcinoma.
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there is little controversy about the benefit of clear resection 
margin (52,60,62,66,83,84), the definition of adequate 
margin width remains a topic of debate (85-88). We had 
recently reviewed our patients who has resection for ICC 
and found that margin width tends to be more important in 
patients who have solitary and node negative tumour, this 
finding is echoed the another study by Farges et al. (84).
Liver transplantation is a well-recognized treatment 
for HCC with 5-year survival ranges from 71% to 87% in 
patient within certain criteria (89-93). However, similar 
result was not reproduced and poor outcomes were reported 
in patients with ICC receiving liver transplantation (94,95). 
A large cohort for liver transplantation for ICC extracted 
from the European Liver Transplant showed that the 
5-year survival was only 29% (96), other studies suggest 
high tumour recurrence rate of 51% to 80% (97,98). Liver 
transplantation for ICC should be limited to highly selected 
patients or under research setting.
Non-surgical treatment for intrahepatic 
cholangiocarcinoma (ICC)
Transarterial chemoembolization (TACE) and transarterial 
radioembolization (TARE) are established treatments 
for unresectable HCC without extrahepatic disease. 
Despite these treatments were intrinsically designed for 
hypervascular tumours like HCC, it has been applied to 
ICC. A number of case series has suggested TACE/TARE 
possess satisfactory safety profile and efficacy with response 
rate of 70–86% and median survival ranging from 11 to 
13 months (99-101).
External radiotherapy could be given to patients with 
unresectable ICC hoping to provide local control and 
prolong survival. A 36% response rate was reported 
for patients who receive a median total of 50 Gy given 
in 2 Gy per section 5 times a week (102). In order to 
minimize radiation exposure to the normal liver tissue, 
stereotactic radiotherapy technique can be used (103). 
A study reported that, with the use of lower radiation 
dose 30 Gy, the disease control and median survival after 
receiving stereotactic radiotherapy was 55% and 11 months 
respectively with significant toxicity was observed (104). 
Adjuvant radiotherapy after curative surgery was shown by 
a retrospective series to be better than surgery alone (105). 
However, before the emergence of higher level of evidence 
or further clinical studies, adjuvant radiotherapy should be 
recommended in selected patients, i.e., positive margin, or 
nodal disease (106).
Being a mediator of hepatic inflammatory process, 
cholangiocyte is equipped with the ability to initiate and 
maintain carcinogenesis, making cholangiocarcinoma 
inherently resistant to chemotherapy (107,108). Response 
rate for classical single agent gemcitabine is at best 30% 
with median survival of 5–14 months (109-114). As 
proven by some clinical trials, combining gemcitabine 
with platinum group chemotherapeutic agent can 
increase response rate to up to 50%, and median survival 
of the patients was also prolonged (115-117), such that 
combination gemcitabine and oxaliplatin/cisplatin has 
become the standard chemotherapeutic regime in many 
centers. Furthermore, advances in bioinformatics would 
allow more oncogenes taking part in the carcinogenetic 
pathway for ICC to be identified (118); further clinical 
trials focusing on combination chemotherapy with targeted 
therapy are expected to be emerging (119-121).
Conclusions
ICC is an uncommon and sinister hepatic malignancy. 
Predisposed patient groups should be offered surveillance 
with sophisticated imaging modalities. Diagnosis at early 
stage with aggressive surgical resection remains the only 
hope of cure in a small proportion of the ICC patients. 
Various non-surgical treatments are available but the 
prognoses are generally guarded. Further clinical trials 
focusing on newly chemotherapeutic and molecular targeted 
regimen are early awaited.
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